AUTHOR=Li Yiqing , Wang Yujie , Chen Yunfei , Wang Yao , Zhang Shaojun , Liu Pan , Chen Zhilin , Song Peng , Luo Lei , Luo Yingying , Dang Yiping , Zhao Lei 

TITLE=Corilagin Ameliorates Atherosclerosis in Peripheral Artery Disease via the Toll-Like Receptor-4 Signaling Pathway in vitro and in vivo

JOURNAL=Frontiers in Immunology

VOLUME=Volume 11 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01611

DOI=10.3389/fimmu.2020.01611

ISSN=1664-3224

ABSTRACT=This study tried to explore whether corilagin would ameliorate or reverse the atherosclerotic development via toll-like receptor 4 (TLR4) signaling pathway in vitro and in vivo. Ana-1 cells or Mouse Peritoneal Macrophages (MPMs) were stimulated with ox-LDL followed by corilagin treating in gradient of concentration. TLR4 expression in Ana-1 cells was up-regulated by lentiviral transduction and down-regulated by siRNA. Peripheral blood mononuclear cells (PBMCs), plasma samples and femoral arteries were collected from rat peripheral artery disease (PAD) models. Both mRNA and protein expression of TLR4 and downstream molecules were significant decreased by corilagin in Ana-1 cells, MPMs and PBMCs from animal models, and the reduction was still existing either down- or up-regulate TLR4 in Ana-1 cells. Corilagin also exerted a prominent effect on the changes in plasma cytokines and the pathological manifestation of atherosclerosis in femoral arteries. Corilagin could ameliorate the development of atherosclerotic plaque via inhibiting TLR4 signal pathway in monocyte/macrophage and reducing the release of inflammatory cytokines. This study provided a new therapeutic target and the new nichetargeting drug to oppose atherosclerosis and showed the enormous potential of Corilagin to control PAD in human.